The drug-device combination product is based on small peptide (P-15) technology that accelerates new bone formation in patients with degenerative disc disease.
for use in anterior cervical discectomy and fusion (ACDF) procedures in 2015. I‑FACTOR bone graft has over 10 years of clinical success in Europe and was approved in the U.S. evaluating the safety and efficacy of our next-generation bone graft in transforaminal lumbar interbody fusion (TLIF) surgery.”
Ifactor ortho trial#
Marx, Ph.D., president, and chief operating officer. “These results are especially encouraging as we continue to advance an investigational device exemption (IDE) clinical trial in the U.S. “We are very encouraged by the results of this level-1 human clinical study in an extremely challenging environment,” said Jeffrey G. “This is now our fourth prospective clinical study in which i-FACTOR Bone Graft has demonstrated a clear clinical benefit and builds upon our previously reported fusion in various spine applications.” “This study is a valuable addition to our clinical evidence base,” said Glen Kashuba, chief executive officer of Cerapedics. Longer term follow-up to evaluate the maintenance of clinical outcomes is in process. Patient reported outcomes at baseline and follow-up were similar between the two groups. Results showed the fusion rate was significantly higher in the i-FACTOR bone graft group (50 percent) compared to the allograft group (20 percent) at one year (p <0.001). Participants suffered from degenerative spondylolisthesis and underwent decompression and non-instrumented posterolateral fusion surgery, randomized to either i-FACTOR bone graft or fresh frozen allograft bone, both mixed with local bone graft. Michael Kjær Jacobsen, at the Center for Spine Surgery and Research in Southern Denmark, led the double-blind, prospective, randomized study in more than 100 patients (60 years or older). “i-FACTOR shows an increased fusion rate versus allograft.”ĭr. Michael Kjær Jacobsen, principal investigator. “In Scandinavia, surgeons often consider performing non-instrumented fusion when there is instability in elderly patients, but allograft bone has notoriously low fusion rates in this population,” said Dr.
Ifactor ortho plus#
The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate compared to allograft plus local bone. WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ - Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article.
0 kommentar(er)
